down arrow

Gain Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US36269B1052
USD
3.50
0.44 (14.38%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.173.50

52 Week

1.413.65
Valuation
Technical
Day's Volume

CASH

879.33 k

Shareholding (Jun 2025)

FII

3.79%

Held by 10 FIIs

DII

92.72%

Held by 4 DIIs

Promoter

0.00%

How big is Gain Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Gain Therapeutics, Inc. has a market capitalization of 51.21 million, with net sales of 0.00 million and a net profit of -20.93 million over the latest four quarters. The company reported shareholder's funds of 7.34 million and total assets of 12.12 million as of Dec 24.

Market Cap: As of Jun 18, Gain Therapeutics, Inc. has a market capitalization of 51.21 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Gain Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -20.93 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 7.34 million and total assets of 12.12 million.

Read More

What does Gain Therapeutics, Inc. do?

22-Jun-2025

Gain Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net loss of $5 million and a market cap of $51.21 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -362.08%.

Overview:<BR>Gain Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 51.21 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.47<BR>- Return on Equity: -362.08%<BR>- Price to Book: 8.86<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is Gain Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 15, 2025, Gain Therapeutics, Inc. shows a mildly bearish trend with daily moving averages indicating bearishness, while weekly indicators suggest mild bullishness, and the stock has underperformed the S&P 500 year-to-date with a return of -21.3%.

As of 15 August 2025, the technical trend for Gain Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly MACD and KST show mildly bullish signals. However, Bollinger Bands and OBV are both bearish, which adds to the overall caution. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -21.3% compared to the S&P 500's 12.22%, although it has a 1-year return of 14.86% versus 17.14% for the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 63 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.65

stock-summary
Return on Equity

-503.05%

stock-summary
Price to Book

17.02

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
82.29%
0%
82.29%
6 Months
74.13%
0%
74.13%
1 Year
120.82%
0%
120.82%
2 Years
59.09%
0%
59.09%
3 Years
8.02%
0%
8.02%
4 Years
-46.32%
0%
-46.32%
5 Years
0%
0%
0.0%

Gain Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Gain Therapeutics, Inc. technically bullish or bearish?

As of 15 August 2025, the technical trend for Gain Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly MACD and KST show mildly bullish signals. However, Bollinger Bands and OBV are both bearish, which adds to the overall caution. In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -21.3% compared to the S&P 500's 12.22%, although it has a 1-year return of 14.86% versus 17.14% for the benchmark....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-177.79%
EBIT to Interest (avg)
-22.96
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.47
Sales to Capital Employed (avg)
0.01
Tax Ratio
2.72%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
20.84%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.95
EV to EBIT
-2.41
EV to EBITDA
-2.42
EV to Capital Employed
-18.05
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-362.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 5 Schemes (3.5%)

Foreign Institutions

Held by 10 Foreign Institutions (3.79%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -28.89% vs -18.42% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.10",
          "val2": "-4.30",
          "chgp": "-18.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.80",
          "val2": "-4.50",
          "chgp": "-28.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.52% vs -26.70% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-20.30",
          "val2": "-22.20",
          "chgp": "8.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.40",
          "val2": "-22.30",
          "chgp": "8.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-403,282.60%",
          "chgp": "40,328.26%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.10
-4.30
-18.60%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.80
-4.50
-28.89%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -28.89% vs -18.42% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-20.30
-22.20
8.56%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-20.40
-22.30
8.52%
Operating Profit Margin (Excl OI)
0.00%
-403,282.60%
40,328.26%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 8.52% vs -26.70% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Gain Therapeutics, Inc. stock-summary
stock-summary
Gain Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."